BOSTON--(BUSINESS WIRE)--Gentuity, LLC, an advanced imaging technology firm, today announced the first human use of the Vis-MTM High-Frequency Optical Coherence Tomography (HF-OCT) imaging system and probe. This represents a significant technological advance for the field of neurointervention, making high resolution intravascular imaging in the brain possible.

“This is an incredibly exciting milestone. The direct visualization technology we evaluated here offers unprecedented potential in the diagnosis and treatment of aneurysms, stroke, intra-cranial atherosclerotic disease (ICAD) and other neurological pathologies,” said Vitor Mendes Pereira, MD. “I am proud and honored to have the opportunity to perform the first cases. The system and imaging probes performed very well, integrating with our workflow seamlessly, and provided us with important information that we cannot obtain with any other technology - very impressive.”

The procedures were performed at St. Michael’s Hospital, a site of Unity Health Toronto, by neurosurgeon Prof. Vitor Mendes Pereira, Director of Endovascular Research and Innovation. They were performed in the neuro-angiography suite with a minimally invasive, endovascular approach.
“We are very pleased to have had the opportunity to work with the team at St. Michael’s Hospital and to contribute our novel high-resolution intracranial images to the care of these patients,” said David Kolstad, CEO of Gentuity. “These procedures reflect years of technical innovation, development, and extensive testing. They are an important step in our mission to develop a platform that will improve the understanding of target diseases, facilitate the development of novel therapies, and ensure optimal treatment delivery for the benefit of patients worldwide.”

Gentuity’s Vis-M neuro intravascular imaging probe has been designed to specifically address the challenges of navigating through the tortuous and delicate blood vessels of the brain. This imaging probe enables in-vivo micron level resolution at 250 frames per second providing high resolution images not only of the arterial wall and interventional therapies but also beyond the vessel wall.

This first-in-world experience will be presented in January at the ABC WIN Conference in Val d’Isere France.

“Because of Neuro HF-OCT, we will now be able, for the first time, to analyze and better understand different pathologies and the results of our neurointerventional therapies. It is a real game changer in the cerebrovascular field,” said Prof. Pedro Lylyk MD, Neurosurgeon, Director and CEO of ENERI (Equipo de Neurocirugía Endovascular y Radiología Intervencionista) in Buenos Aires, Argentina.

CT Homepage